Drug Profile
Research programme: multiple sclerosis therapies - Biogen
Alternative Names: BIIB 053; Death receptor-6 antagonists - Biogen; DR6 antagonists - Biogen IdecLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class
- Mechanism of Action Death domain receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
- 05 Aug 2014 Preclinical development is ongoing in USA